Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a ...
Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...
ThePrint on MSN4d
Why Indian patients groups are opposing patent requests for blockbuster HIV drug lenacapavirGranting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to ...
Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Malignant Pleural Mesothelioma.
The US-based Gilead Sciences’ long-acting injectable HIV drug lenacapavir is at the centre of a patent opposition case ...
Gilead Sciences has struck a deal to work with privately held Genesis Therapeutics to use generative artificial intelligence to discover and develop novel, small-molecule therapies across multiple ...
Gilead Sciences, Inc. and Genesis Therapeutics, Inc. have announced that the companies have entered into a strategic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback